Genmab — April 2020
-
sgen negative estimeret eps på USD -0,99. market cap 21B USD. de må have andet end TV i pipeline for fremtidig indtjening....
-
amivantamab in phase II according this JNJ slide https://twitter.com/semodough/status/1250827516161527810/photo/1
-
I think it has been phase2 since dec 2018 ? At least according to other sources. There is a part 2 to the study https://clinicaltrials.gov/ct2/show/NCT02609776 Originally it was n=180 ?
-
God morgen
-
Genmab A/S (NASDAQ:GMAB) - SunTrust Banks boosted their FY2020 EPS estimates for shares of Genmab A/S in a research note issued to investors on Tuesday, April 14th. SunTrust Banks analyst A. Goonewardene now forecasts that the company will earn $0.24 per share for the year, up from their previous estimate of $0.23. SunTrust Banks has a "Buy" rating on the stock. SunTrust Banks also issued estimates for Genmab A/S's FY2022 earnings at $0.80 EPS and FY2023 earnings at $1.01 EPS.
-
GMAB has been the topic of a number of other research reports. Zacks Investment Research raised shares of Genmab A/S from a "sell" rating to a "hold" rating in a research report on Thursday, February 27th. HC Wainwright reduced their price target on Genmab A/S from $29.00 to $28.00 and set a "buy" rating for the company in a research report on Wednesday. Royal Bank of Canada reiterated a "buy" rating and issued a $27.00 target price on shares of Genmab A/S in a report on Monday, April 6th. Final
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind